CA1146866A — Process for the production of sustained release pharmaceutical composition of solid medical material
Assigned to Yamanouchi Pharmaceutical Co Ltd · Expires 1983-05-24 · 43y expired
What this patent protects
ABSTRACT OF THE DISCLOSURE Sustained release pharmaceutical compositions of solid medical material contains the amorphous solid medical material, polyethylene oxide, and at last one basic substance selected from the group consisting of hydroxy-propylmethyl cellulose, hydroxyp…
USPTO Abstract
ABSTRACT OF THE DISCLOSURE Sustained release pharmaceutical compositions of solid medical material contains the amorphous solid medical material, polyethylene oxide, and at last one basic substance selected from the group consisting of hydroxy-propylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate metal acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid. Optionally, the composition may further contain another basic substance selected from the group consisting of surface active agent, polyethylene glycol, propylene glycol, glycerin, glycerin fatty acid ester and vegetable oil. According to another aspect of the invention, a sustained release pharmaceutical composition of amorphous nicardipine compounded with polyethylene oxide is provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.